IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless. The company said that the study "narrowly missed" the ...
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) Between March 19, 2019, and February 13, 2023, 41 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback